Fresenius Kabi USA, LLC — Lobbying Disclosure | Poliscope

Fresenius Kabi USA, LLC

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$7.8M

Filings

Firms Hired

Active Period

2013–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$3,380,000	10	3
2025	$1,877,941	13	3
2024	$1,333,913	9	2
2023	$962,895	8	2
2022	$100,000	9	2
2021	$100,000	4	1
2020	$75,000	5	1
2019	—	2	1
2014	—	1	1
2013	—	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
Fresenius Kabi USA, LLC	$7,829,749	33
WEST FRONT STRATEGIES LLC	—	13
FEROX STRATEGIES	—	8
CGCN GROUP, LLC	—	6
PENN AVENUE PARTNERS	—	4

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	56
HOUSE OF REPRESENTATIVES	53
Health & Human Services, Dept of (HHS)	39
White House Office	34
Food & Drug Administration (FDA)	31
Centers For Medicare and Medicaid Services (CMS)	27
Patent & Trademark Office (PTO)	23
Commerce, Dept of (DOC)	18
U.S. Trade Representative (USTR)	14
Executive Office of the President (EOP)	9
Natl Economic Council (NEC)	6
Labor, Dept of (DOL)	5
Office of Management & Budget (OMB)	4
Defense, Dept of (DOD)	3
Office of Science & Technology Policy (OSTP)	2
Veterans Affairs, Dept of (VA)	2

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Trade (domestic/foreign)	Trade (domestic/foreign)	47
Medicare/Medicaid	Medicare/Medicaid	44
Pharmacy	Pharmacy	37
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	35
Health Issues	Health Issues	33
Copyright/Patent/Trademark	Copyright/Patent/Trademark	21
Manufacturing	Manufacturing	17
Tariff (miscellaneous tariff bills)	Tariff (miscellaneous tariff bills)	8
Budget/Appropriations	Budget/Appropriations	3
Disaster Planning/Emergencies	Disaster Planning/Emergencies	1
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	1
Accounting	Accounting	1
Science/Technology	Science/Technology	1
Labor Issues/Antitrust/Workplace	Labor Issues/Antitrust/Workplace	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 10369119th Congress

Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026

2026 · third_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 10369: Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act S. 43/H.R. 26485: Skinny Labels, Big Savings Act S. 3549/H.R. 6837: PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act Toxic-Free Medical Devices Drug Enforcement Administration Quotas Department of Labor Proposed and Final PBM Transparency Rule 340b Contract Pharmacies

Client expense: $630,000 · Firm income: —

Matched citations: H.R. 10369

H.R. 3269119th Congress

ETHIC Act

2026 · third_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 10369: Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act S. 43/H.R. 26485: Skinny Labels, Big Savings Act S. 3549/H.R. 6837: PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act Toxic-Free Medical Devices Drug Enforcement Administration Quotas Department of Labor Proposed and Final PBM Transparency Rule 340b Contract Pharmacies

Client expense: $630,000 · Firm income: —

Matched citations: H.R. 3269

H.R. 5526119th Congress

Biosimilar Red Tape Elimination Act

2026 · third_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 10369: Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act S. 43/H.R. 26485: Skinny Labels, Big Savings Act S. 3549/H.R. 6837: PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act Toxic-Free Medical Devices Drug Enforcement Administration Quotas Department of Labor Proposed and Final PBM Transparency Rule 340b Contract Pharmacies

Client expense: $630,000 · Firm income: —

Matched citations: H.R. 5526

H.R. 6837119th Congress

To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.

2026 · third_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 10369: Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act S. 43/H.R. 26485: Skinny Labels, Big Savings Act S. 3549/H.R. 6837: PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act Toxic-Free Medical Devices Drug Enforcement Administration Quotas Department of Labor Proposed and Final PBM Transparency Rule 340b Contract Pharmacies

Client expense: $630,000 · Firm income: —

Matched citations: H.R. 6837

Show 21 more cited filings

S. 1414119th Congress

Expedited Access to Biosimilars Act

2026 · third_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 10369: Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act S. 43/H.R. 26485: Skinny Labels, Big Savings Act S. 3549/H.R. 6837: PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act Toxic-Free Medical Devices Drug Enforcement Administration Quotas Department of Labor Proposed and Final PBM Transparency Rule 340b Contract Pharmacies

Client expense: $630,000 · Firm income: —

Matched citations: S. 1414

S. 1954119th Congress

Biosimilar Red Tape Elimination Act

2026 · third_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 10369: Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act S. 43/H.R. 26485: Skinny Labels, Big Savings Act S. 3549/H.R. 6837: PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act Toxic-Free Medical Devices Drug Enforcement Administration Quotas Department of Labor Proposed and Final PBM Transparency Rule 340b Contract Pharmacies

Client expense: $630,000 · Firm income: —

Matched citations: S. 1954

S. 2276119th Congress

ETHIC Act

2026 · third_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 10369: Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act S. 43/H.R. 26485: Skinny Labels, Big Savings Act S. 3549/H.R. 6837: PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act Toxic-Free Medical Devices Drug Enforcement Administration Quotas Department of Labor Proposed and Final PBM Transparency Rule 340b Contract Pharmacies

Client expense: $630,000 · Firm income: —

Matched citations: S. 2276

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · third_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 10369: Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act S. 43/H.R. 26485: Skinny Labels, Big Savings Act S. 3549/H.R. 6837: PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act Toxic-Free Medical Devices Drug Enforcement Administration Quotas Department of Labor Proposed and Final PBM Transparency Rule 340b Contract Pharmacies

Client expense: $630,000 · Firm income: —

Matched citations: S. 2658

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · third_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) PTAB: Proposed Rule, Settled Expectations, Patent Thickets and Ancillary Product Patents, Discretionary Denials

Client expense: $630,000 · Firm income: —

Matched citations: S. 2658

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · third_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) Domestic Manufacturing of Essential Medicines

Client expense: $630,000 · Firm income: —

Matched citations: S. 2658

S. 3549119th Congress

PBM FAIR Act

2026 · third_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 10369: Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act S. 43/H.R. 26485: Skinny Labels, Big Savings Act S. 3549/H.R. 6837: PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act Toxic-Free Medical Devices Drug Enforcement Administration Quotas Department of Labor Proposed and Final PBM Transparency Rule 340b Contract Pharmacies

Client expense: $630,000 · Firm income: —

Matched citations: S. 3549

S. 43119th Congress

Skinny Labels, Big Savings Act

2026 · third_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 10369: Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act S. 43/H.R. 26485: Skinny Labels, Big Savings Act S. 3549/H.R. 6837: PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act Toxic-Free Medical Devices Drug Enforcement Administration Quotas Department of Labor Proposed and Final PBM Transparency Rule 340b Contract Pharmacies

Client expense: $630,000 · Firm income: —

Matched citations: S. 43

H.R. 3269119th Congress

ETHIC Act

2026 · second_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act PTAB Proposed Rule - Discretionary Denials and One and Done Domestic Production of Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Use of Industrial Chemicals in Medical Devices Drug Shortages and Supply Chain Resilience Employee Benefits Security Administration (EBSA) Proposed Rule Re: Broker/Consultant Transparency to Employer Plans Section 301 Investigation re: Germany Issues PBM Transparency: Implementation of Consolidated Appropriations Act (CAA) Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars Net Elective Cost Policy: PBM Reform Through Bid Transparency

Client expense: $580,000 · Firm income: —

Matched citations: H.R. 3269

H.R. 5526119th Congress

Biosimilar Red Tape Elimination Act

2026 · second_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act Section 301 Investigation re: Germany Issues Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines PTAB Proposed Rule - Discretionary Denials and One and Done Federal Procurement Preferences for Domestic Medicines Drug Shortages and Supply Chain Resilience

Client expense: $580,000 · Firm income: —

Matched citations: H.R. 5526

H.R. 5526119th Congress

Biosimilar Red Tape Elimination Act

2026 · second_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act PTAB Proposed Rule - Discretionary Denials and One and Done Domestic Production of Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Use of Industrial Chemicals in Medical Devices Drug Shortages and Supply Chain Resilience Employee Benefits Security Administration (EBSA) Proposed Rule Re: Broker/Consultant Transparency to Employer Plans Section 301 Investigation re: Germany Issues PBM Transparency: Implementation of Consolidated Appropriations Act (CAA) Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars Net Elective Cost Policy: PBM Reform Through Bid Transparency

Client expense: $580,000 · Firm income: —

Matched citations: H.R. 5526

S. 1414119th Congress

Expedited Access to Biosimilars Act

2026 · second_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act PTAB Proposed Rule - Discretionary Denials and One and Done Domestic Production of Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Use of Industrial Chemicals in Medical Devices Drug Shortages and Supply Chain Resilience Employee Benefits Security Administration (EBSA) Proposed Rule Re: Broker/Consultant Transparency to Employer Plans Section 301 Investigation re: Germany Issues PBM Transparency: Implementation of Consolidated Appropriations Act (CAA) Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars Net Elective Cost Policy: PBM Reform Through Bid Transparency

Client expense: $580,000 · Firm income: —

Matched citations: S. 1414

S. 1414119th Congress

Expedited Access to Biosimilars Act

2026 · second_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act Section 301 Investigation re: Germany Issues Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines PTAB Proposed Rule - Discretionary Denials and One and Done Federal Procurement Preferences for Domestic Medicines Drug Shortages and Supply Chain Resilience

Client expense: $580,000 · Firm income: —

Matched citations: S. 1414

S. 1954119th Congress

Biosimilar Red Tape Elimination Act

2026 · second_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act PTAB Proposed Rule - Discretionary Denials and One and Done Domestic Production of Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Use of Industrial Chemicals in Medical Devices Drug Shortages and Supply Chain Resilience Employee Benefits Security Administration (EBSA) Proposed Rule Re: Broker/Consultant Transparency to Employer Plans Section 301 Investigation re: Germany Issues PBM Transparency: Implementation of Consolidated Appropriations Act (CAA) Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars Net Elective Cost Policy: PBM Reform Through Bid Transparency

Client expense: $580,000 · Firm income: —

Matched citations: S. 1954

S. 1954119th Congress

Biosimilar Red Tape Elimination Act

2026 · second_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act Section 301 Investigation re: Germany Issues Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines PTAB Proposed Rule - Discretionary Denials and One and Done Federal Procurement Preferences for Domestic Medicines Drug Shortages and Supply Chain Resilience

Client expense: $580,000 · Firm income: —

Matched citations: S. 1954

S. 2276119th Congress

ETHIC Act

2026 · second_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act PTAB Proposed Rule - Discretionary Denials and One and Done Domestic Production of Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Use of Industrial Chemicals in Medical Devices Drug Shortages and Supply Chain Resilience Employee Benefits Security Administration (EBSA) Proposed Rule Re: Broker/Consultant Transparency to Employer Plans Section 301 Investigation re: Germany Issues PBM Transparency: Implementation of Consolidated Appropriations Act (CAA) Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars Net Elective Cost Policy: PBM Reform Through Bid Transparency

Client expense: $580,000 · Firm income: —

Matched citations: S. 2276

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · second_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act PTAB Proposed Rule - Discretionary Denials and One and Done Domestic Production of Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Use of Industrial Chemicals in Medical Devices Drug Shortages and Supply Chain Resilience Employee Benefits Security Administration (EBSA) Proposed Rule Re: Broker/Consultant Transparency to Employer Plans Section 301 Investigation re: Germany Issues PBM Transparency: Implementation of Consolidated Appropriations Act (CAA) Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars Net Elective Cost Policy: PBM Reform Through Bid Transparency

Client expense: $580,000 · Firm income: —

Matched citations: S. 2658

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · second_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Drug Shortages and Supply Chain Resilience PBM Transparency: Implementation of Consolidated Appropriations Act (CAA) Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars Net Elective Cost Policy: PBM Reform Through Bid Transparency

Client expense: $580,000 · Firm income: —

Matched citations: S. 2658

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · second_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) PTAB Proposed Rule - Discretionary Denials and One and Done Ancillary Product Patent Reform

Client expense: $580,000 · Firm income: —

Matched citations: S. 2658

H.R. 3269119th Congress

ETHIC Act

2026 · first_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2296: National Defense Authorization Act (NDAA) for Fiscal Year 2026 Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR Medical Device Safety FDA Streamlining FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining FY27 National Defense Authorization Act - Domestic Production of Essential Medicines CMS Preference for Domestic Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform Net Elective Cost Policy: PBM Reform Through Bid Transparency Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC) Procurement

Client expense: $1,100,000 · Firm income: —

Matched citations: H.R. 3269

S. 2276119th Congress

ETHIC Act

2026 · first_quarter · Firm: Fresenius Kabi USA, LLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2296: National Defense Authorization Act (NDAA) for Fiscal Year 2026 Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR Medical Device Safety FDA Streamlining FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining FY27 National Defense Authorization Act - Domestic Production of Essential Medicines CMS Preference for Domestic Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform Net Elective Cost Policy: PBM Reform Through Bid Transparency Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC) Procurement

Client expense: $1,100,000 · Firm income: —

Matched citations: S. 2276

Source: Senate LDA